179 related articles for article (PubMed ID: 9144006)
1. Serum levels of soluble Fas/APO-1 receptor in human retroviral infection and associated diseases.
Kamihira S; Yamada Y; Hiragata Y; Yamaguchi T; Izumikawa K; Matsuo Y; Sugahara K; Tsuruta K; Atogami S; Tsukasaki K; Maeda T; Tomonaga M
Intern Med; 1997 Mar; 36(3):166-70. PubMed ID: 9144006
[TBL] [Abstract][Full Text] [Related]
2. Soluble and membrane isoforms of Fas/CD95 in fresh adult T-cell leukemia (ATL) cells and ATL-cell lines.
Sugahara K; Yamada Y; Hiragata Y; Matsuo Y; Tsuruda K; Tomonaga M; Maeda T; Atogami S; Tsukasaki K; Kamihira S
Int J Cancer; 1997 Jul; 72(1):128-32. PubMed ID: 9212233
[TBL] [Abstract][Full Text] [Related]
3. Discrepant expression of membrane and soluble isoforms of Fas (CD95/APO-1) in adult T-cell leukaemia: soluble Fas isoform is an independent risk factor for prognosis.
Kamihira S; Yamada Y; Tomonaga M; Sugahara K; Tsuruda K
Br J Haematol; 1999 Dec; 107(4):851-60. PubMed ID: 10606894
[TBL] [Abstract][Full Text] [Related]
4. Plasma soluble fas and soluble fas ligand in chronic glomerulonephritis.
Sano H; Asano K; Minatoguchi S; Hiraoka J; Fujisawa K; Nishigaki K; Yasuda N; Kumada H; Takemura M; Ohashi H; Seishima M; Fujiwara T; Fujiwara H
Nephron; 1998 Oct; 80(2):153-61. PubMed ID: 9736812
[TBL] [Abstract][Full Text] [Related]
5. Soluble Fas/Apo-1 (CD95) levels during T cell activation in the presence of acute myelogenous leukemia accessory cells; contributions from local release and variations in systemic levels.
Bruserud O; Ulvestad E
Cancer Immunol Immunother; 2000 Sep; 49(7):377-87. PubMed ID: 10999464
[TBL] [Abstract][Full Text] [Related]
6. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma.
Mouawad R; Khayat D; Soubrane C
Melanoma Res; 2000 Oct; 10(5):461-7. PubMed ID: 11095407
[TBL] [Abstract][Full Text] [Related]
7. Soluble form of Fas and Fas ligand in serum and bronchoalveolar lavage fluid of individuals infected with human T-lymphotropic virus type 1.
Sakamoto N; Mukae H; Fujii T; Kakugawa T; Kaida H; Kadota J; Kohno S
Respir Med; 2004 Mar; 98(3):213-9. PubMed ID: 15002756
[TBL] [Abstract][Full Text] [Related]
8. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases.
Nozawa K; Kayagaki N; Tokano Y; Yagita H; Okumura K; Hasimoto H
Arthritis Rheum; 1997 Jun; 40(6):1126-9. PubMed ID: 9182923
[TBL] [Abstract][Full Text] [Related]
9. An increase of soluble Fas, an inhibitor of apoptosis, associated with progression of COPD.
Yasuda N; Gotoh K; Minatoguchi S; Asano K; Nishigaki K; Nomura M; Ohno A; Watanabe M; Sano H; Kumada H; Sawa T; Fujiwara H
Respir Med; 1998 Aug; 92(8):993-9. PubMed ID: 9893764
[TBL] [Abstract][Full Text] [Related]
10. Soluble fas levels correlate with multiple organ dysfunction severity, survival and nitrate levels, but not with cellular apoptotic markers in critically ill patients.
Papathanassoglou ED; Moynihan JA; Vermillion DL; McDermott MP; Ackerman MH
Shock; 2000 Aug; 14(2):107-12. PubMed ID: 10947151
[TBL] [Abstract][Full Text] [Related]
11. Characterization of soluble FAS, FAS ligand and tumour necrosis factor-alpha in patients with chronic HCV infection.
Raghuraman S; Abraham P; Daniel HD; Ramakrishna BS; Sridharan G
J Clin Virol; 2005 Sep; 34(1):63-70. PubMed ID: 16087126
[TBL] [Abstract][Full Text] [Related]
12. Prolonged intrathecal release of soluble Fas following severe traumatic brain injury in humans.
Lenzlinger PM; Marx A; Trentz O; Kossmann T; Morganti-Kossmann MC
J Neuroimmunol; 2002 Jan; 122(1-2):167-74. PubMed ID: 11777556
[TBL] [Abstract][Full Text] [Related]
13. Increased serum levels of soluble Fas in progressive B-CLL.
Osorio LM; Aguilar-Santelises M; De Santiago A; Hachiya T; Mellstedt H; Jondal M
Eur J Haematol; 2001 May; 66(5):342-6. PubMed ID: 11422415
[TBL] [Abstract][Full Text] [Related]
14. Correlation of loss of CD4 T cells with plasma levels of both soluble form Fas (CD95) Fas ligand (FasL) in HIV-infected infants.
Hosaka N; Oyaizu N; Than S; Pahwa S
Clin Immunol; 2000 Apr; 95(1 Pt 1):20-5. PubMed ID: 10794428
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of circulating soluble Fas and Fas ligand in patients with acute myocardial infarction.
Ohtsuka T; Hamada M; Sasaki O; Suzuki M; Hara Y; Shigematsu Y; Ohtani T; Honda T; Hiwada K
Coron Artery Dis; 1999 Jun; 10(4):221-5. PubMed ID: 10376200
[TBL] [Abstract][Full Text] [Related]
16. Plasma-soluble Fas (APO-1, CD95) and soluble Fas ligand in immune thrombocytopenic purpura.
Yoshimura C; Nomura S; Nagahama M; Ozaki Y; Kagawa H; Fukuhara S
Eur J Haematol; 2000 Apr; 64(4):219-24. PubMed ID: 10776692
[TBL] [Abstract][Full Text] [Related]
17. Serum sFAS levels are elevated in ANCA-positive vasculitis compared with other autoimmune diseases.
Christensson M; Pettersson E; Eneslätt K; Christensson B; Bratt J; Rantapää-Dahlqvist S; Sundqvist KG
J Clin Immunol; 2002 Jul; 22(4):220-7. PubMed ID: 12148596
[TBL] [Abstract][Full Text] [Related]
18. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure.
Nishigaki K; Minatoguchi S; Seishima M; Asano K; Noda T; Yasuda N; Sano H; Kumada H; Takemura M; Noma A; Tanaka T; Watanabe S; Fujiwara H
J Am Coll Cardiol; 1997 May; 29(6):1214-20. PubMed ID: 9137215
[TBL] [Abstract][Full Text] [Related]
19. Proinflammatory cytokine activation is linked to apoptotic mediator, soluble Fas level in patients with chronic heart failure.
Kinugawa T; Kato M; Yamamoto K; Hisatome I; Nohara R
Int Heart J; 2012; 53(3):182-6. PubMed ID: 22790687
[TBL] [Abstract][Full Text] [Related]
20. Elevated serum levels of soluble interleukin-2 receptors in HTLV-I--associated myelopathy.
Yamaguchi K; Nishimura Y; Kiyokawa T; Takatsuki K
J Lab Clin Med; 1989 Oct; 114(4):407-10. PubMed ID: 2794753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
